Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12175055 | 0.92 | MEN1 (0.37) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL2712148 | 0.92 | MEN1 (0.37) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL15116717 | 0.91 | TSHR (0.37) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL15116645 | 0.91 | GAA (0.36) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL15116541 | 0.88 | USP2 (0.38) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL16409146 | 0.86 | GHSR (0.39) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL142219 | 0.84 | MEN1 (0.39) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL15116710 | 0.83 | GAA (0.43) | MEN1KMT2AMAPK1GHSRAPLNR | |
| SCHEMBL2392486 | 0.82 | KMT2A (0.38) | MEN1KMT2AMAPK1GHSRCTSL | |
| SCHEMBL1820679 | 0.82 | MAPT (0.39) | MEN1KMT2AMAPK1GHSRCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| CN-110997661-B | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220323595-A1 | SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES | NOVARTIS AG (CH) | 2022-10-13 | — | — | US | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20200376129-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10751417-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-25 | — | — | US | disclosed |
| CN-110997661-A | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2020-04-10 | — | — | CN | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | MEN1 4830/4885KMT2A 2995/4885MAPK1 1413/4885 |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | MEN1 4563/4885KMT2A 4752/4885MAPK1 958/4885 |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | ABCB11, ABCB1, GHRHR | MEN1 2713/4885KMT2A 1725/4885MAPK1 2336/4885 |
| US-20200376129-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | ABCB11, ABCB1, GHRHR | MEN1 2713/4885KMT2A 1725/4885MAPK1 2336/4885 |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MEN1 4676/4885KMT2A 4624/4885MAPK1 3142/4885 |
| US-10751417-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | MEN1 2713/4885KMT2A 1725/4885MAPK1 2336/4885 |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | MEN1 4563/4885KMT2A 4752/4885MAPK1 958/4885 |
| US-20220323595-A1 | SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES | TEK, VEGFA, FLT4 | MEN1 695/4885KMT2A 3702/4885MAPK1 3278/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | MEN1 206/4885KMT2A 977/4885MAPK1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.